Vivus Reports Weak Diet-Drug Sales: AttorneyOne Informs Alleged Threat from Fen Phen Remains

As Market Watch published on November 6th, 2012, Vivus reported weak Qsymia diet-drug sales since its launch in September. Qsymia includes phentermine, a stimulant included in Fen Phen which was linked with heart valve damage and primary pulmonary hypertension (PPH). Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Fen Phen severe adverse events [http://www.attorneyone.com/fen-phen-lawsuits/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Fen Phen: severe adverse events threat

Fen Phen: severe adverse events threat

withdrawn from the market in 1997 as it was linked with heart valve damage and primary pulmonary hypertension (PPH)

San Diego, CA (PRWEB) December 05, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who filed a Phen Phen Lawsuit. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

As Market Watch published on November 6th, 2012, Vivus reported weak Qsymia diet-drug sales since its launch in September. According to the company, a third of patients were choosing not to fill their prescriptions because of the cost. Qsymia includes phentermine, a stimulant included in Fen Phen. Fen Phen, a popular Wyeth obesity drug, was withdrawn from the market in 1997 as it was linked with heart valve damage and primary pulmonary hypertension (PPH).

Findings of the 2008 study, published in BMC Medicine, indicate that many individuals that had taken Fen Phen in the past were found to have heart valve damage up to 7 years later.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Fen Phen, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that the alleged threat from Fen Phen remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

According to court documents, on September 27th, 2012, the lawsuit filed by Lois Munchel in Delaware District Court (case no. 1:2012cv00906), alleging primary pulmonary hypertension from fenfluramine and phentermine, was transferred to the Fen Phen Multidistrict Litigation (MDL No. 1203).

AttorneyOne informs you that if someone has already filed a claim and received a settlement but their condition deteriorated overtime they may be eligible for further compensation.

AttorneyOne.com has further information on Fen Phen lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/12/prweb10199958.htm.